SG170830A1 - Renin inhibitors for the treatment of hypertension - Google Patents

Renin inhibitors for the treatment of hypertension

Info

Publication number
SG170830A1
SG170830A1 SG201102387-6A SG2011023876A SG170830A1 SG 170830 A1 SG170830 A1 SG 170830A1 SG 2011023876 A SG2011023876 A SG 2011023876A SG 170830 A1 SG170830 A1 SG 170830A1
Authority
SG
Singapore
Prior art keywords
hypertension
treatment
renin inhibitors
methods
cessation
Prior art date
Application number
SG201102387-6A
Other languages
English (en)
Inventor
Andrew Satlin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38420678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG170830(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG170830A1 publication Critical patent/SG170830A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG201102387-6A 2006-04-03 2007-03-30 Renin inhibitors for the treatment of hypertension SG170830A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78884206P 2006-04-03 2006-04-03

Publications (1)

Publication Number Publication Date
SG170830A1 true SG170830A1 (en) 2011-05-30

Family

ID=38420678

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201102387-6A SG170830A1 (en) 2006-04-03 2007-03-30 Renin inhibitors for the treatment of hypertension

Country Status (20)

Country Link
US (1) US20090062395A1 (enExample)
EP (1) EP2004167A1 (enExample)
JP (1) JP2009532494A (enExample)
KR (1) KR20080108515A (enExample)
CN (1) CN101415413A (enExample)
AU (1) AU2007234917B2 (enExample)
BR (1) BRPI0710095A2 (enExample)
CA (1) CA2645260A1 (enExample)
CL (1) CL2007000912A1 (enExample)
IL (1) IL193905A0 (enExample)
MA (1) MA30387B1 (enExample)
MX (1) MX2008012729A (enExample)
NO (1) NO20084625L (enExample)
NZ (1) NZ571251A (enExample)
RU (1) RU2008143055A (enExample)
SG (1) SG170830A1 (enExample)
TN (1) TNSN08383A1 (enExample)
TW (1) TW200806283A (enExample)
WO (1) WO2007118023A1 (enExample)
ZA (1) ZA200807615B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087116A1 (en) * 2008-01-11 2009-07-16 Novartis Ag Use of spp100 for the treatment of acute mi
CN102212012A (zh) * 2010-04-12 2011-10-12 上海源力生物技术有限公司 一种合成阿利克伦的中间体及其制备方法
EP2768971A1 (en) 2011-10-20 2014-08-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the detection and the treatment of cardiac remodeling
AU2020259450A1 (en) * 2019-04-18 2021-11-18 EyePoint Pharmaceuticals, Inc. Methods of treating hypertension with activators of Tie-2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5659065A (en) * 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5606078A (en) * 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
JP2005537822A (ja) * 2002-06-28 2005-12-15 ノバルティス アクチエンゲゼルシャフト 有機化合物の使用
US20040266743A1 (en) * 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
WO2005037317A2 (en) * 2003-10-17 2005-04-28 Cornell Research Foundation, Inc. Mast cell-derived renin
MY148773A (en) * 2004-03-17 2013-05-31 Novartis Ag Galenic formulations of organic compounds
ES2310293T3 (es) * 2004-09-27 2009-01-01 Pantarhei Bioscience B.V. Tratamiento o prevencion de sangrados no programados en mujeres bajo medicacion que contiene progestogeno.

Also Published As

Publication number Publication date
US20090062395A1 (en) 2009-03-05
MX2008012729A (es) 2008-10-14
MA30387B1 (fr) 2009-05-04
AU2007234917A1 (en) 2007-10-18
NO20084625L (no) 2008-11-03
IL193905A0 (en) 2009-08-03
EP2004167A1 (en) 2008-12-24
CL2007000912A1 (es) 2008-03-14
TW200806283A (en) 2008-02-01
JP2009532494A (ja) 2009-09-10
KR20080108515A (ko) 2008-12-15
BRPI0710095A2 (pt) 2011-08-02
WO2007118023A1 (en) 2007-10-18
AU2007234917B2 (en) 2011-05-12
CA2645260A1 (en) 2007-10-18
NZ571251A (en) 2011-12-22
ZA200807615B (en) 2009-10-28
TNSN08383A1 (en) 2009-12-29
CN101415413A (zh) 2009-04-22
RU2008143055A (ru) 2010-05-10

Similar Documents

Publication Publication Date Title
ZA202208783B (en) Kras mutant protein inhibitors
DE60329001D1 (en) 8-hydroxychinolinderivate
MX2009004984A (es) Metodos para conservar la funcion renal utilizando inhibidores de oxidoreductasa de xantina.
IL193252A0 (en) N-hydroxyacrylamide compounds
WO2008024439A3 (en) 4-aminoquinazoline derivatives and methods of use thereof
WO2008033798A3 (en) A pyrrolopyrazin as syk-kinase inhibitor
MY153243A (en) Compound for inhibiting mitotic progression
WO2010108074A3 (en) Inhibitors of pi3 kinase
WO2009155121A3 (en) Inhibitors of pi3 kinase
UA95955C2 (ru) Ингибиторы обратной транскриптазы вич
MX2012002752A (es) Compuestos de heteroarilo como inhibidores de cinasa.
WO2007101232A3 (en) Inhibition of jak2 as a treatment of pulmonary arterial hypertension
GEP20125708B (en) Hydroxamate-based inhibitors of deacetylases b
WO2008064866A8 (en) Treatment for multiple myeloma
WO2009086426A3 (en) Soluble epoxide hydrolase inhibitors for the treatment of endothelial dysfunction
WO2008109991A8 (en) Inhibitors of carnitine palmitoyltransferase and treating cancer
IL178100A0 (en) 5-amino-4-hydroxy-7-(1h-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension
WO2007019153A3 (en) Methods for treating hypertension
TNSN08383A1 (en) Renin inhibitors for the treatment of hypertension
WO2007056324A3 (en) Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
MX2007004020A (es) Uso de inhibidores de renina para la prevencion o tratamiento de disfuncion diastolica o falla cardiaca diastolica.
WO2009148600A8 (en) Deuterated lysine-based compounds
MX2009012704A (es) Inhibidores de transcriptasa inversa de no nucleosidos.
WO2012119006A3 (en) Derivatives of pyrazole-substituted amino-heteroaryl compounds
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof